Novel biochemical risk factors for type 2 diabetes: pathogenic insights or prediction possibilities?

[1]  Ross J. Harris,et al.  Gamma-Glutamyltransferase Is Associated With Incident Vascular Events Independently of Alcohol Intake: Analysis of the British Women’s Heart and Health Study and Meta-Analysis , 2007, Arteriosclerosis, thrombosis, and vascular biology.

[2]  A. Chetrit,et al.  Predicting the 20‐year diabetes incidence rate , 2007, Diabetes/metabolism research and reviews.

[3]  K. Chien.  An Accurate Risk Score Based on Anthropometric, Dietary, and Lifestyle Factors to Predict the Development of Type 2 Diabetes , 2007, Diabetes Care.

[4]  P. Whincup,et al.  Circulating adiponectin levels and mortality in elderly men with and without cardiovascular disease and heart failure. , 2007, Archives of internal medicine.

[5]  J. Manson,et al.  Circulating Levels of Endothelial Adhesion Molecules and Risk of Diabetes in an Ethnically Diverse Cohort of Women , 2007, Diabetes.

[6]  Bess Dawson-Hughes,et al.  The role of vitamin D and calcium in type 2 diabetes. A systematic review and meta-analysis. , 2007, The Journal of clinical endocrinology and metabolism.

[7]  Ralph B D'Agostino,et al.  Prediction of incident diabetes mellitus in middle-aged adults: the Framingham Offspring Study. , 2007, Archives of internal medicine.

[8]  J. Pankow,et al.  Original Contribution a Prospective Study of Plasma Ferritin Level and Incident Diabetes the Atherosclerosis Risk in Communities (aric) Study , 2022 .

[9]  Allan Vaag,et al.  Interleukin-1-receptor antagonist in type 2 diabetes mellitus. , 2007, The New England journal of medicine.

[10]  L. Chambless,et al.  Sex Differences in the Prediction of Type 2 Diabetes by Inflammatory Markers , 2007, Diabetes Care.

[11]  N. Forouhi,et al.  Serial Metabolic Measurements and Conversion to Type 2 Diabetes in the West of Scotland Coronary Prevention Study , 2007, Diabetes.

[12]  K. Walsh,et al.  Adiponectin actions in the cardiovascular system. , 2007, Cardiovascular research.

[13]  M. Sandhu,et al.  Elevated serum ferritin levels predict new-onset type 2 diabetes: results from the EPIC-Norfolk prospective study , 2007, Diabetologia.

[14]  Theo Stijnen,et al.  Genetic Variation, C-Reactive Protein Levels, and Incidence of Diabetes , 2007, Diabetes.

[15]  G. Lowe,et al.  Effects of tumor necrosis factor blockade on cardiovascular risk factors in psoriatic arthritis: a double-blind, placebo-controlled study. , 2007, Arthritis and rheumatism.

[16]  P. Macfarlane,et al.  C-Reactive Protein and Prediction of Coronary Heart Disease and Global Vascular Events in the Prospective Study of Pravastatin in the Elderly at Risk (PROSPER) , 2007, Circulation.

[17]  M. Quon,et al.  Reciprocal relationships between abnormal metabolic parameters and endothelial dysfunction , 2007, Current opinion in lipidology.

[18]  B. Tomlinson,et al.  Impact of TNF inhibition on insulin resistance and lipids levels in patients with rheumatoid arthritis , 2007, Clinical Rheumatology.

[19]  D. Levy,et al.  Multiple biomarkers for the prediction of first major cardiovascular events and death. , 2006, The New England journal of medicine.

[20]  G. Hotamisligil,et al.  Inflammation and metabolic disorders , 2006, Nature.

[21]  E. Barrett-Connor,et al.  Association of adiponectin with coronary heart disease and mortality: the Rancho Bernardo study. , 2006, American journal of epidemiology.

[22]  J. Arch,et al.  Comment on: Schmidt MI, Duncan BB, Vigo A et al. (2006) Leptin and incident type 2 diabetes: risk or protection? Diabetologia 49:2086–2096 , 2006, Diabetologia.

[23]  J. Karbowska,et al.  Role of adiponectin in the regulation of carbohydrate and lipid metabolism. , 2006, Journal of physiology and pharmacology : an official journal of the Polish Physiological Society.

[24]  B. Pedersen,et al.  The role of IL-6 in mediating the anti-inflammatory effects of exercise. , 2006, Journal of physiology and pharmacology : an official journal of the Polish Physiological Society.

[25]  Michaela Diamant,et al.  Alanine aminotransferase as a marker of non‐alcoholic fatty liver disease in relation to type 2 diabetes mellitus and cardiovascular disease , 2006, Diabetes/metabolism research and reviews.

[26]  T. Funahashi,et al.  Associations of Adiponectin Levels With Incident Impaired Glucose Metabolism and Type 2 Diabetes in Older Men and Women , 2006, Diabetes Care.

[27]  B. Howard,et al.  Plasminogen activator inhibitor‐1 and the risk of Type 2 diabetes mellitus in American Indians: the Strong Heart Study , 2006, Diabetic medicine : a journal of the British Diabetic Association.

[28]  L. Weinehall,et al.  A combination of HbA1c, fasting glucose and BMI is effective in screening for individuals at risk of future type 2 diabetes: OGTT is not needed , 2006, Journal of internal medicine.

[29]  J. Danesh,et al.  Adiponectin and Coronary Heart Disease: A Prospective Study and Meta-Analysis , 2006, Circulation.

[30]  Juan P Casas,et al.  Insight into the nature of the CRP-coronary event association using Mendelian randomization. , 2006, International journal of epidemiology.

[31]  J. Pankow,et al.  Leptin and incident type 2 diabetes: risk or protection? , 2006, Diabetologia.

[32]  Eric Boerwinkle,et al.  An assessment of incremental coronary risk prediction using C-reactive protein and other novel risk markers: the atherosclerosis risk in communities study. , 2006, Archives of internal medicine.

[33]  Lu Tian,et al.  Narrative Review: Assessment of C-Reactive Protein in Risk Prediction for Cardiovascular Disease , 2006, Annals of Internal Medicine.

[34]  S. Anderson,et al.  Insulin-like growth factor binding protein-2 (IGFBP-2) is a marker for the metabolic syndrome. , 2006, Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association.

[35]  S. Gabriel,et al.  PAI‐1 Gene 4G/5G Polymorphism and Risk of Type 2 Diabetes in a Population‐based Sample , 2006, Obesity.

[36]  S. Haffner,et al.  Progression of Plasminogen Activator Inhibitor-1 and Fibrinogen Levels in Relation to Incident Type 2 Diabetes , 2006, Circulation.

[37]  E. Ding,et al.  Sex differences of endogenous sex hormones and risk of type 2 diabetes: a systematic review and meta-analysis. , 2006, JAMA.

[38]  S. Cummings,et al.  Adipocytokines and incident diabetes mellitus in older adults: the independent effect of plasminogen activator inhibitor 1. , 2006, Archives of internal medicine.

[39]  A. Häkkinen,et al.  Overproduction of large VLDL particles is driven by increased liver fat content in man , 2006, Diabetologia.

[40]  R. D'Agostino,et al.  Hemostatic markers of endothelial dysfunction and risk of incident type 2 diabetes: the Framingham Offspring Study. , 2006, Diabetes.

[41]  Tom R. Gaunt,et al.  C-reactive protein and its role in metabolic syndrome: mendelian randomisation study , 2005, The Lancet.

[42]  Barbara Thorand,et al.  Elevated Markers of Endothelial Dysfunction Predict Type 2 Diabetes Mellitus in Middle-Aged Men and Women From the General Population , 2005, Arteriosclerosis, thrombosis, and vascular biology.

[43]  P. Whincup,et al.  Hepatic enzymes, the metabolic syndrome, and the risk of type 2 diabetes in older men. , 2005, Diabetes care.

[44]  T. Mandrup-Poulsen,et al.  Interleukin-6 and diabetes: the good, the bad, or the indifferent? , 2005, Diabetes.

[45]  T. Valle,et al.  Improved fibrinolysis by an intensive lifestyle intervention in subjects with impaired glucose tolerance. The Finnish Diabetes Prevention Study , 2005, Diabetologia.

[46]  G. Zoppini,et al.  Non‐alcoholic hepatic steatosis and its relation to increased plasma biomarkers of inflammation and endothelial dysfunction in non‐diabetic men. Role of visceral adipose tissue , 2005, Diabetic medicine : a journal of the British Diabetic Association.

[47]  C. Stehouwer,et al.  “Vasocrine” signalling from perivascular fat: a mechanism linking insulin resistance to vascular disease , 2005, The Lancet.

[48]  S. Ebrahim,et al.  What can mendelian randomisation tell us about modifiable behavioural and environmental exposures? , 2005, BMJ : British Medical Journal.

[49]  S. Fowler,et al.  Intensive lifestyle intervention or metformin on inflammation and coagulation in participants with impaired glucose tolerance. , 2005, Diabetes.

[50]  K. Petersen,et al.  Reversal of nonalcoholic hepatic steatosis, hepatic insulin resistance, and hyperglycemia by moderate weight reduction in patients with type 2 diabetes. , 2005, Diabetes.

[51]  P. Macfarlane,et al.  Elevated alanine aminotransferase predicts new-onset type 2 diabetes independently of classical risk factors, metabolic syndrome, and C-reactive protein in the west of Scotland coronary prevention study. , 2004, Diabetes.

[52]  David Couper,et al.  Adiponectin and the development of type 2 diabetes: the atherosclerosis risk in communities study. , 2004, Diabetes.

[53]  D. Befroy,et al.  Mechanism of Hepatic Insulin Resistance in Non-alcoholic Fatty Liver Disease* , 2004, Journal of Biological Chemistry.

[54]  Nader Rifai,et al.  Plasma adiponectin levels and risk of myocardial infarction in men. , 2004, JAMA.

[55]  J. Manson,et al.  Biomarkers of endothelial dysfunction and risk of type 2 diabetes mellitus. , 2004, JAMA.

[56]  Vilmundur Gudnason,et al.  C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. , 2004, The New England journal of medicine.

[57]  Nader Rifai,et al.  Inflammatory markers and risk of developing type 2 diabetes in women. , 2004, Diabetes.

[58]  J. Manson,et al.  Body iron stores in relation to risk of type 2 diabetes in apparently healthy women. , 2004, JAMA.

[59]  J. Jansson,et al.  High levels of tissue plasminogen activator (tPA) antigen precede the development of type 2 diabetes in a longitudinal population study. The Northern Sweden MONICA Study , 2003, Cardiovascular diabetology.

[60]  S. Haffner.  Insulin resistance, inflammation, and the prediabetic state. , 2003, The American journal of cardiology.

[61]  M. Igarashi,et al.  Decreased serum levels of adiponectin are a risk factor for the progression to type 2 diabetes in the Japanese Population: the Funagata study. , 2003, Diabetes care.

[62]  J. Pankow,et al.  Low-grade systemic inflammation and the development of type 2 diabetes: the atherosclerosis risk in communities study. , 2003, Diabetes.

[63]  T. Funahashi,et al.  Inflammatory markers, adiponectin, and risk of type 2 diabetes in the Pima Indian. , 2003, Diabetes care.

[64]  Z. Bloomgarden,et al.  Inflammation and insulin resistance. , 2003, Diabetes care.

[65]  A. Hamsten,et al.  Regulation of Plasma PAI-1 Concentrations in HAART-Associated Lipodystrophy During Rosiglitazone Therapy , 2003, Arteriosclerosis, thrombosis, and vascular biology.

[66]  Jaakko Tuomilehto,et al.  The diabetes risk score: a practical tool to predict type 2 diabetes risk. , 2003, Diabetes care.

[67]  Joachim Spranger,et al.  Inflammatory cytokines and the risk to develop type 2 diabetes: results of the prospective population-based European Prospective Investigation into Cancer and Nutrition (EPIC)-Potsdam Study. , 2003, Diabetes.

[68]  H. Boeing,et al.  Adiponectin and protection against type 2 diabetes mellitus , 2003, The Lancet.

[69]  S. Haffner,et al.  Effect of Rosiglitazone Treatment on Nontraditional Markers of Cardiovascular Disease in Patients With Type 2 Diabetes Mellitus , 2002, Circulation.

[70]  Jonathan Krakoff,et al.  Adiponectin and development of type 2 diabetes in the Pima Indian population , 2002, The Lancet.

[71]  D. Dunger,et al.  Circulating concentrations of insulin-like growth factor-I and development of glucose intolerance: a prospective observational study , 2002, The Lancet.

[72]  N. Sattar,et al.  C-reactive protein is an independent predictor of risk for the development of diabetes in the West of Scotland Coronary Prevention Study. , 2002, Diabetes.

[73]  S. Haffner,et al.  Identification of Persons at High Risk for Type 2 Diabetes Mellitus: Do We Need the Oral Glucose Tolerance Test? , 2002, Annals of Internal Medicine.

[74]  S. Haffner,et al.  Elevated levels of acute-phase proteins and plasminogen activator inhibitor-1 predict the development of type 2 diabetes: the insulin resistance atherosclerosis study. , 2002, Diabetes.

[75]  J. Pankow,et al.  Sensitivity and specificity of anthropometrics for the prediction of diabetes in a biracial cohort. , 2001, Obesity research.

[76]  J. Danesh,et al.  Soluble adhesion molecules and prediction of coronary heart disease: a prospective study and meta-analysis , 2001, The Lancet.

[77]  J. Manson,et al.  C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. , 2001, JAMA.

[78]  N. Day,et al.  Vitamin C and hyperglycemia in the European Prospective Investigation into Cancer--Norfolk (EPIC-Norfolk) study: a population-based study. , 2000, Diabetes care.

[79]  T. Valle,et al.  The Finnish Diabetes Prevention Study , 2000, British Journal of Nutrition.

[80]  N. Wareham,et al.  Diabetes risk score: towards earlier detection of Type 2 diabetes in general practice , 2000, Diabetes/metabolism research and reviews.

[81]  S. Humphries,et al.  Inflammation, obesity, stress and coronary heart disease: is interleukin-6 the link? , 2000, Atherosclerosis.

[82]  B. Duncan,et al.  Factor VIII and other hemostasis variables are related to incident diabetes in adults. The Atherosclerosis Risk in Communities (ARIC) Study. , 1999, Diabetes care.

[83]  H. Lakka,et al.  Relation between iron stores and non-insulin dependent diabetes in men: case-control study , 1998, BMJ.

[84]  R. Berg,et al.  A Systematic Review and Meta-analysis , 2010 .

[85]  D. Catellier,et al.  Atherosclerosis Risk in Communities (ARIC) Study , 2009 .

[86]  S. Kaneko,et al.  Insulin resistance accelerates a dietary rat model of nonalcoholic steatohepatitis. , 2007, Gastroenterology.

[87]  G. King,et al.  Mechanisms of Disease: endothelial dysfunction in insulin resistance and diabetes , 2007, Nature Clinical Practice Endocrinology &Metabolism.

[88]  M. Gonzalez-gay,et al.  Anti-tumor necrosis factor-α blockade improves insulin resistance in patients with rheumatoid arthritis , 2006 .

[89]  Neil R. Powe,et al.  The Atherosclerosis Risk in Communities Study , 2006 .

[90]  M. Sandhu.  Insulin-like growth factor-I and risk of type 2 diabetes and coronary heart disease: molecular epidemiology. , 2005, Endocrine development.

[91]  H. Delves.  Effect of inflammatory response on trace element and vitamin status. , 2001, Annals of clinical biochemistry.

[92]  E. Boyko,et al.  Association between baseline plasma leptin levels and subsequent development of diabetes in Japanese Americans. , 1999, Diabetes care.

[93]  S. Haffner.  Sex hormone-binding protein, hyperinsulinemia, insulin resistance and noninsulin-dependent diabetes. , 1996, Hormone research.